Top of the morning, and a fine one it is. A shiny sun and deliciously cool breeze are enveloping the Pharmalot campus, which has quieted down now that the short people have left for the local schoolhouse and gainful employment, respectively. As for us, we are brewing still more cups of stimulation — we continue to favor the seasonal pumpkin spice — and foraging for items of interest. On that note, we present you the menu below. We hope your journey today is rewarding and you conquer the world. But do find time to keep in touch. Good luck, everyone …
A new poll found that former Celgene (CELG) executive chairman Bob Hugin is locked in a statistical dead heat for the U.S. Senate race in New Jersey with the incumbent, Sen. Bob Menendez, The Hill writes. Menendez, a Democrat, has been dogged by accusations of corruption. But the poll also found that Hugin is being hit by his tenure at Celgene as 51 percent of respondents believe it is an extremely important or significant factor that the company is accused of profiting off an expensive cancer drug.
About the Author Reprints
Concerning the FDA on ‘over-dosing,’ it does seem history repeats itself (from 2007): https://www.medpagetoday.com/pediatrics/generalpediatrics/7469 )